NPI: 1346200334 · BALTIMORE, MD 21225 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 03/24/2006
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 03/24/2006 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 12,477 | $29K |
| 2019 | 10,832 | $58K |
| 2020 | 7,028 | $94K |
| 2021 | 8,451 | $123K |
| 2022 | 8,599 | $154K |
| 2023 | 6,530 | $162K |
| 2024 | 1,301 | $66K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 10,377 | 1,355 | $527K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 23,495 | 1,340 | $86K |
| J1270 | Injection, doxercalciferol, 1 mcg | 10,086 | 936 | $26K |
| J1756 | Injection, iron sucrose, 1 mg | 3,153 | 931 | $23K |
| 83970 | 929 | 856 | $19K | |
| J0887 | Injection, epoetin beta, 1 microgram, (for esrd on dialysis) | 22 | 12 | $3K |
| A4657 | Syringe, with or without needle, each | 2,549 | 1,494 | $2K |
| 85048 | 1,166 | 1,086 | $0.00 | |
| 83540 | 473 | 442 | $0.00 | |
| 85041 | 1,149 | 1,080 | $0.00 | |
| 82728 | 471 | 442 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 20 | 17 | $0.00 |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 863 | 546 | $0.00 |
| 83550 | 425 | 397 | $0.00 | |
| 82607 | 20 | 17 | $0.00 | |
| 82746 | 20 | 17 | $0.00 |